The new deal will allow clinicians to use the UroNav device to annotate and biopsy targeted prostate tissue and localize the tissue appropriate for ablation directly with its Sonablate software, Charlotte, N.C.-based SonaCare said.
“This is a major strategic partnership for SonaCare. Working together, Invivo and SonaCare are putting in place a broad product portfolio for performing advanced diagnostics, targeted ablation, and systematic patient follow up, as well as a means for delivering that platform to the market. These are very exciting times for both of our organizations and for the physicians and patients they serve around the world,” SonaCare CEO Dr. Mark Carol said in a press release.
The companies said that along with the licensing deal, they also created a “selling relationship” that will allow Invivo’s sales representatives to sell Sonablate to nearly 200 U.S.-based UroNav facilities.
“We’re excited about this new alliance with SonaCare and the value this will bring to our mutual customers. Achieving compatibility between our respective products provides Sonablate customers with much easier access to Invivo’s integrated portfolio of Prostate Oncology Solutions, including our market-leading UroNav Fusion Biopsy System. We look forward to working together with SonaCare to provide our customers and their patients with innovative clinical solutions throughout the care continuum,” Invivo strategy & business dev senior director Thomas Tynes said in preapred remarks.
Last October, SonaCare said it won FDA pre market approval for its high intensity focused ultrasound device designed to treat prostate cancer, causing competitor EDAP (NSDQ:EDAP) to yank the de novo application for its Ablatherm HIFU.
The Sonablate is SonaCare’s 2nd medical device to win clearance, having won 510(k) clearance for its Sonatherm laparoscopic high intensity therapeutic ablation device.